Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ISTA Reports Rise In Q3 Net Revenue
ISTA Pharmaceuticals (ISTA) reported that net revenue for the three and nine months ended September 30, 2009 was $32m and $76.4m respectively, an increase of 47% and 39%,
ISTA Pharmaceuticals (ISTA) reported that net revenue for the three and nine months ended September 30, 2009 was $32m and $76.4m respectively, an increase of 47% and 39%,
As part of a strategic initiative to expand the group’s limited presence in China, Novartis has entered into an agreement to acquire 85% stake in Zhejiang Tianyuan Bio-Pharmaceutical
Unilife Medical Solutions (Unilife Australia) has entered into a merger implementation agreement with Unilife Corporation (Unilife USA) to facilitate the proposed redomiciliation of the Unilife group in the
NovaRx has received FDA approval for a Special Protocol Assessment (SPA) Protocol Amendment to the pivotal Lucanix phase III clinical trial in patients with non-small cell lung cancer
Link Technologies has reported the commercialisation and launch of a range of unlocked-nucleic acid (UNA) monomers under license from RiboTask. Under the terms of the agreement Link is
PharmaForm, a wholly owned subsidiary of Akela Pharma has enhanced its portfolio of bioavailability enhancement solutions by adding aqueous and solvent spray drying. PharmaForm claimed that its processing
ProChon Biotech has selected Lonza’s Hopkinton facility to manufacture its proprietary fibroblast growth factor (FGF2v) variant in the US. FGF2v is a key regulator of cellular processes involved
Scynexis has received a payment for meeting certain milestones in its multi-year research collaboration with Merial Limited, which began in 2005. Scynexis, focuses considerable medicinal chemistry, advanced biological
Takeda Pharmaceuticals North America has established Takeda Pharmaceuticals Mexico, which will be headquartered in Mexico City. The company said that the expansion strengthens the company’s North American presence,
Pfizer has exercised its option to license Flamel Technologies’ (Flamel) Medusa technology for the development of a controlled release formulation of an already-marketed therapeutic protein. Flamel is expected